Literature DB >> 1794255

Flow cytometric and biochemical analysis of dose-dependent effects of sodium butyrate on human endometrial adenocarcinoma cells.

S Saito1, H A Crissman, M Nishijima, T Kagabu, I Nishiya, L S Cram.   

Abstract

Sodium butyrate (SB) treatment was previously shown to produce seven-fold increases in estrogen hormone receptor binding sites of human endometrial adenocarcinoma (IK) cells. Flow cytometric analysis and histone gel electrophoresis were used to examine cell cycle, cell metabolism, and nuclear histone fractions in IK cells treated with different concentrations of SB. SB-treated cells stained with fluorochromes specific for DNA, RNA, or general protein were analyzed by flow cytometry (FCM). Changes in accessibility to three DNA stains and gel electrophoresis were used to analyze rearrangements in chromatin structure. SB caused an accumulation of cells in the G1 phase and inhibited DNA synthesis, but not cellular levels of RNA and protein. Hoechst accessibility to A-T rich regions on DNA was dramatically increased after removal of SB. H1 histones were dephosphorylated and core histones were acetylated during SB-treatment. Information obtained in these studies may be useful for correlating cellular and biochemical events with SB-induced increases in nuclear steroid hormone binding sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1794255     DOI: 10.1002/cyto.990120810

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  3 in total

1.  Cellular ras activity is required for passage through multiple points of the G0/G1 phase in BALB/c 3T3 cells.

Authors:  S Dobrowolski; M Harter; D W Stacey
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

2.  Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells.

Authors:  D Coradini; C Pellizzaro; D Marimpietri; G Abolafio; M G Daidone
Journal:  Cell Prolif       Date:  2000-06       Impact factor: 6.831

3.  Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate.

Authors:  L Qiu; M J Kelso; C Hansen; M L West; D P Fairlie; P G Parsons
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.